ONCODEduce ABL1 Kinase Domain Mutation NGS Panel
Product Description:
NGS Panel to detect Tyrosine Kinase Inhibitors (TKIs) resistance mutations in ABL1 kinase domain and BCR-ABL1 fusions.
Gene Covered -- BCR-ABL1 fusion and mutation in ABL1 kinase domain (amino acid positions 244-396)
Technique:
Next Generation Sequencing (NGS)
Test Methodology:
RNA extracted from blood/ marrow/ aspirate smears is subjected to amplification-based library preparation and massively parallel sequencing. This assay is designed to capture the fusion event from both ends, enabling independent detection of a single fusion event, and resulting in an internal, orthogonal verification of these fusions. Sequencing analysis is performed using commercial bioinformatics pipelines and annotation is done using proprietary and public databases.
Specimen Requirements:
3ml of Blood or Marrow Aspirate in EDTA tube or
2 aspirate smears with adequate cellularity
Turn Around Time:
15 working days
Shipment Requirement:
Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.